Full-Time
Posted on 9/10/2024
Develops mRNA-based medicines for health
Senior, Expert
Norwood, MA, USA
Position based at the Norwood, MA site.
Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treatment options for patients. Unlike traditional pharmaceuticals, which often rely on chemical compounds, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to harness the power of mRNA to improve patient outcomes and transform the landscape of medical treatments.
Company Size
5,001-10,000
Company Stage
IPO
Total Funding
$6.5B
Headquarters
Cambridge, Massachusetts
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
The high-profile lawsuit between Pfizer, BioNTech, and Moderna over mRNA COVID-19 vaccine patents remains one of the most closely watched cases in 2025.
Moderna Inc. expects to launch a personalized cancer vaccine that it's developing with Merck & Co. by 2027, one of its top executives said.
Moderna was awarded the contract from the U.S. Department of Health and Human Services in January during the Biden administration to accelerate development of its mRNA-based vaccine, and as part of an effort to address growing concerns of a bird flu pandemic in humans.
Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billionSubmitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccineCAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024."We have made progress in 2024 across our late-stage pipeline and cost reduction efforts. Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023," said Stéphane Bancel, Chief Executive Officer of Moderna. "In 2025, we remain focused on driving sales, delivering up to 10 product approvals through 2027, and expanding cost efficiencies across our business. By the end of 2025, we aim to remove nearly $1 billion in costs. With strong momentum in our late-stage pipeline, we anticipate multiple approvals starting this year, along with key Phase 3 readouts that will support our long-term growth."Recent progress includes:Commercial UpdatesModerna is entering 2025 with two approved products, Spikevax® and mRESVIA®.COVID-19: The Company reported $923 million in Spikevax® sales in the fourth quarter of 2024, which includes $244 million of U.S